The utility of local and systemic interleukin 6 (IL-6) as a prognostic marker in incident peritoneal dialysis (PD) patients remains to be fully defined. The present study aimed to explore the capacity of systemic IL-6 concentrations to predict cardiovascular events (CVEs) and mortality in PD patients, and to evaluate the influence of neutral-pH PD solutions low in glucose degradation products (GDPs) on systemic IL-6.
Methods
The study included 175 incident participants from the balANZ trial with at least one stored serum sample. A composite CVE score was used as the primary clinical outcome measure. Multilevel linear regression and Poisson regression models were fitted to describe, respectively, the trend of serum IL-6 over time and its ability to predict composite CVE.
Results
A significant increase in serum IL-6 from baseline to 24 months was observed in the study population (mean difference: 1.68 pg/mL; p = 0.006). The type of PD solution received by patients exerted no significant effect on serum IL-6 (p = 0.12). Composite CVE was significantly and independently associated with baseline serum IL-6 (incidence rate ratio per picogram per milliliter: 1.06; 95% confidence interval: 1.02 to 1.10; p = 0.003).
Conclusions
Baseline serum IL-6 was a significant independent predictor of composite CVE. Serum IL-6 concentrations increased with increasing PD duration and were not significantly modified with the use of biocompatible fluid over the study period. The present study is the first to link systemic IL-6 concentrations with CVE outcomes in incident PD patients.
JohnsonD.W., DentH., HawleyC.M., McDonaldS.P., RosmanJ.B., BrownF.G.Association of dialysis modality and cardiovascular mortality in incident dialysis patients.Clin J Am Soc Nephrol2009; 4: 1620–8.
2.
BeckerA.E., de BoerO.J., van der WalA.C.The role of inflammation and infection in coronary artery disease.Annu Rev Med2001; 52: 289–97.
3.
WilliamsJ.D., CraigK.J., TopleyN., Von RuhlandC., FallonM., NewmanG.R.Morphologic changes in the peritoneal membrane of patients with renal disease.J Am Soc Nephrol2002; 13: 470–9.
4.
AyuzawaN., IshibashiY., TakazawaY., KumeH., FujitaT.Peritoneal morphology after long-term peritoneal dialysis with biocompatible fluid: recent clinical practice in Japan.Perit Dial Int2012; 32: 159–67.
5.
MortierS., FaictD., SchalkwijkC.G., LameireN.H., De VrieseA.S.Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane.Kidney Int2004; 66: 1257–65.
6.
MortierS., LameireN.H., De VrieseA.S.The effects of peritoneal dialysis solutions on peritoneal host defense.Perit Dial Int2004; 24: 123–38.
7.
JohnsonD.W., BrownF.G., ClarkeM., BoudvilleN., EliasT.J., FooM.W.The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial.Perit Dial Int2012; 32: 497–506.
HurstS.M., WilkinsonT.S., McLoughlinR.M., JonesS., HoriuchiS., YamamotoN.IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation.Immunity2001; 14: 705–14.
10.
HumphriesS.E., LuongL.A., OggM.S., HaweE., MillerG.J.The interleukin-6-174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men.Eur Heart J2001; 22: 2243–52.
11.
VerduijnM., MarechalC., CoesterA.M., SampimonD.E., BoeschotenE.W., DekkerF.W.The –174G/C variant of IL6 as risk factor for mortality and technique failure in a large cohort of peritoneal dialysis patients.Nephrol Dial Transplant2012; 27: 3516–23.
12.
LiuY., Berthier–SchaadY., FallinM.D., FinkN.E., TracyR.P., KlagM.J.IL-6 haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort.J Am Soc Nephrol2006; 17: 863–70.
13.
ZoccaliC., TripepiG., MallamaciF.Dissecting inflammation in ESRD: do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients?J Am Soc Nephrol2006; 17(Suppl 3): S169–73.
14.
JohnsonD.W., BrownF.G., ClarkeM., BoudvilleN., EliasT.J., FooM.W.Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.J Am Soc Nephrol2012; 23: 1097–107.
15.
JohnsonD.W., ClarkeM., WilsonV., WoodsF., BrownF.G.Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function.BMC Nephrol2010; 11: 25.
16.
JohnsonD.W., BrownF.G., ClarkeM., BoudvilleN., EliasT.J., FooM.W.The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial.Nephrol Dial Transplant2012; 27: 4445–53.
17.
Pecoits–FilhoR., CarvalhoM.J., StenvinkelP., LindholmB., HeimbürgerO.Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis.Perit Dial Int2006; 26: 53–63.
18.
LambieM., ChessJ., DonovanK.L., KimY.L., DoJ.Y., LeeH.B.Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival.J Am Soc Nephrol2013; 24: 2071–80.
19.
ChoJ.H., HurI.K., KimC.D., ParkS.H., RyuH.M., YookJ.M.Impact of systemic and local peritoneal inflammation on peritoneal solute transport rate in new peritoneal dialysis patients: a 1-year prospective study.Nephrol Dial Transplant2010; 25: 1964–73.
20.
SzetoC.C., ChowK.M., LamC.W., LeungC.B., KwanB.C., ChungK.Y.Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products—a 1-year randomized control trial.Nephrol Dial Transplant2007; 22: 552–9.
21.
WeissL., StegmayrB., MalmstenG., TejdeM., HadimeriH., SiegertC.E.Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution.Perit Dial Int2009; 29: 647–55.
LuiS.L., YungS., YimA., WongK.M., TongK.L., WongK.S.A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial.Am J Kidney Dis2012; 60: 966–75.
24.
LaiK.N., LamM.F., LeungJ.C., ChanL.Y., LamC.W., ChanI.H.A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products.Perit Dial Int2012; 32: 280–91.
25.
Pecoits–FilhoR., HeimbürgerO., BárányP., SulimanM., Fehrman– EkholmI., LindholmB.Associations between circulating inflammatory markers and residual renal function in CRF patients.Am J Kidney Dis2003; 41: 1212–18.
26.
WangA.Y., LamC.W., ChanI.H., WangM., LuiS.F., SandersonJ.E.Long-term mortality and cardiovascular risk stratification of peritoneal dialysis patients using a combination of inflammation and calcification markers.Nephrol Dial Transplant2009; 24: 3826–33.
27.
LittleJ., PhillipsL., RussellL., GriffithsA., RussellG.I., DaviesS.J.Longitudinal lipid profiles on CAPD: their relationship to weight gain, comorbidity, and dialysis factors.J Am Soc Nephrol1998; 9: 1931–9.
28.
BaigentC., LandrayM.J., ReithC., EmbersonJ., WheelerD.C., TomsonC.The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.Lancet2011; 377: 2181–92.
29.
PicotteM., CampbellC.G., ThorlandW.G.Day-to-day variation in plasma interleukin-6 concentrations in older adults.Cytokine2009; 47: 162–5.
